Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations Excluding Melanoma and Thyroid Cancer
Study Type: Treatment
Phase: II
NCTID: NCT02465060
Principal Investigator:
Benjamin Powers
A Phase II Study of Brentuximab Vedotin in Combination with Checkpoint Inhibitor CPI Therapy in Subjects with Metastatic Solid Tumors After Progression on Prior PD-1 Inhibitor Treatment
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion before Tumor-Infiltrating Lymphocyte Therapy with Lifileucel in Metastatic Melanoma
Study Type: Treatment
Phase: II
NCTID: NCT06151847
Principal Investigator:
Muhammad Umair Mushtaq
A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD
A Randomized Phase II Study of ATR Inhibition in Advanced PD-L1-refractory Merkel Cell Carcinoma: The MATRiX Trial
Study Type: Treatment
Phase: II
NCTID: NCT05947500
Principal Investigator:
Nina Mathew
Randomized Phase II/III Study Of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab In Patients With Unresectable State III Or Stage IV Melanoma
A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760 and Trametinib NSC-763093 in BRAFV600E/K Mutant Melanoma
A Phase I/II, open-label study of PD-1 knockout tumor-infiltrating lymphocytes IOV-4001 in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
A PHASE III STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Study Type: Treatment
Phase: III
NCTID: NCT06246916
Principal Investigator:
Gary Doolittle